Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Haloperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 0.84 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.84 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.84 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.84 |
| ▸ | HTR1A | P08908 | 3/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.84 |
| ▸ | HRH1 | P35367 | 3/20 | 0.84 |
| ▸ | HTR2C | P28335 | 2/20 | 0.84 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Haloperidol SCHEMBL5452448 | 0.92 | DRD2 (0.72) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL9507217 | 0.92 | DRD2 (0.92) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL5070670 | 0.92 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| SCHEMBL20254453 | 0.92 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8264 | 0.92 | DRD2 (1.00) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL15545886 | 0.91 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL317367 | 0.91 | DRD2 (0.98) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL28699132 | 0.90 | DRD2 (0.96) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL10621893 | 0.90 | DRD2 (0.80) | DRD2ADRA1AHTR1AADRA2AADRA2B | |
| Haloperidol SCHEMBL8741248 | 0.89 | DRD2 (0.94) | DRD2ADRA1AHTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387622-B1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIV VALENCIA (ES) | 2025-05-28 | — | — | EP | claimed |
| US-20240390356-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitá degli Studi di Torino (IT) | 2024-11-28 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4387622-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitat de València (ES) | 2024-06-26 | — | — | EP | claimed |
| WO-2023118164-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2023-06-29 | — | — | WO | claimed |
| EP-4197536-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Universitat de València (ES) | 2023-06-21 | — | — | EP | claimed |
| US-10100362-B2 | Schizophrenia-associated genetic loci identified in genome wide association studies and methods of use thereof | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2018-10-16 | — | — | US | claimed |
| US-20160032390-A1 | SCHIZOPHRENIA-ASSOCIATED GENETIC LOCI IDENTIFIED IN GENOME WIDE ASSOCIATION STUDIES AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2016-02-04 | — | — | US | claimed |
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | claimed |
| US-20060167074-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2006-07-27 | — | — | US | claimed |
| WO-2006023497-A2 | INTRANASAL DELIVERY OF ANTIPSYCHOTIC DRUGS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060039869-A1 | Intranasal delivery of antipsychotic drugs | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2006-02-23 | — | — | US | claimed |
| EP-1627639-A2 | Use of COX-2 inhibitors for the treatment of affective disorders | Müller, Norbert (DE) | 2006-02-22 | — | — | EP | claimed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| WO-2004100899-A2 | USE OF SECRETIN IN TREATMENTS OF DISORDERS ASSOCIATED WITH THE AMYGDALA | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040204469-A1 | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MULLER NORBERT | 2004-10-14 | — | — | US | claimed |
| EP-1397145-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | Müller, Norbert (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | TPH2, MAOB, PTGS2 | DRD2 241/4885HTR2A 18/4885DRD3 707/4885 |
| US-20060167074-A1 | Methods and compositions for the treatment of psychiatric disorders | TPH2, MAOB, PTGS2 | DRD2 241/4885HTR2A 18/4885DRD3 707/4885 |
| US-20240390356-A1 | HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, HTT, MTPN | DRD2 591/4885HTR2A 660/4885DRD3 458/4885 |
| US-20040204469-A1 | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | PTGES2, PTGER2, PTGDR2 | DRD2 15/4885HTR2A 10/4885DRD3 141/4885 |
| US-20060039869-A1 | Intranasal delivery of antipsychotic drugs | HTT, SLC6A3, HTR6 | DRD2 42/4885HTR2A 46/4885DRD3 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.